Background: Little information on costs and quality of life (QoL) of patients with Multiple Sclerosis (MS) has been published for Greece so far.
Introduction
Multiple sclerosis (MS) is the second most common nontraumatic cause of neurological disability in adults worldwide, with a considerable socioeconomic impact, which is disproportionate to the relatively limited prevalence of the disease [1] . In Greece, the estimated prevalence varies with location, ranging between 10.2/100,000 individuals in southern areas [2] and 119.61/100,000 people in western areas [3] , with the most recent estimation being 23 cases per 100,000 individuals in northern areas [4] . Several epidemiological studies have demonstrated a gradual increase in prevalence and incidence of MS in Greece, placing most geographical areas in the medium and high-risk zone [3] [4] [5] [6] [7] . This gradual increase has been ascribed to the advances in diagnostic modalities and overall improved awareness [4] .
The socio-economic burden of MS is particularly high both for patients, their families, as well as the national health system. The average annual cost per patient with MS is higher than for patients with many other, more common, chronic conditions [8, 9] . The economic burden of MS is largely driven by the progression of disability and relapses, while MS-related symptoms of fatigue, depression, cognitive deterioration and behavioral disorders, pain, urinary and sexual dysfunction and comorbidities are also factors in the overall economic impact [10] [11] [12] [13] [14] [15] . MS typically starts in early adulthood, so the disease Although information about costs and QoL of MS patients is available for a number of European countries, no such data have been published for Greece so far. The objective of the study was to assess the health and economic burden that relapsing forms of MS impose to Greek MS patients and the Greek social security fund (EOPYY), respectively.
Materials and Method

Study design and data collection
This was a multicentre, cross-sectional, retrospective, burden of disease study. The subjects were identified from six MS centres from various areas of the country. Adult patients suffering from either remitting-relapsing or secondary progressive MS with relapses were included in the study, provided they had given written informed consent. Patients that had limited capacity to participate in the study procedures, due to cognitive impairment or other factors, or were participating in another clinical study were excluded.
During a single visit, trained researchers completed a case report form by interviewing each patient on: i) demographics, ii) disease data (year of diagnosis, year of first symptoms, type of MS, Expanded Disability Status Scale [EDSS] score, number of relapses), iii) MS related comorbidities, iv) treatment-related information, v) resource utilization (inpatient and outpatient care, diagnostic and laboratory tests, medication, disability equipment, productivity loss and informal caregiving). Additionally, patients self-assessed their HRQoL with the EQ-5D questionnaire.
Costs calculation
This study adopts a bottom-up approach to estimate the mean annual costs per MS patient in Greece, from a social security fund perspective. Since MS is a chronic disease, a prevalence-based approach was selected, taking into account the use of resources during the previous year, using information which was gathered at a single point in time. A prevalence-based economic evaluation provides estimates of costs and health benefits of a certain population for a specific time horizon. Only MS specific resource utilization was collected. Costs were computed as the monetary value of resource utilization, i.e. the number of resource units consumed multiplied by the respective unit cost. Unit costs were obtained from publicly available sources in Greece (Table  1) . MS related comorbidities' economic burden was estimated as the total mean annual cost per patient related to each comorbidity, based on previous relevant literature [9, 26] . Productivity loss of patients was approximated as the income reduction due to MS and the cost related to the early disability pension. The informal care cost was estimated by taking into account the total weekly hours spent for informal care (extrapolated to year), and using the mean gross income for Greece in 2011 (€19,018), divided by the number of hours worked, equally for working and non-working caregivers.
Costs were grouped as: 1) direct medical costs (inpatient and outpatient care, consultations, investigations, treatments and MSrelated comorbidities), 2) direct non-medical costs (equipment investment, professional assistance, informal care) and 3) indirect costs (productivity loss, i.e., disability pension, percentage of income reduction).
QoL
The EQ-5D [27] is a widely used generic instrument for measuring HRQoL. It consists of a descriptive health state classification system with five dimensions, including: 1) mobility, 2) self-care, 3) usual activities, 4) pain/discomfort and 5) anxiety/depression, and a Visual Analogue Scale (VAS) assessing the overall perception of the subject's health state. Each dimension of the descriptive system is measured with an ordinal three-point scale describing three levels of severity: i) no problems, ii) some problems, and iii) extreme problems. Together, these five dimensions with three levels for each dimension define a total of 243 health states, ranging from full to worst health. Health utilities were obtained based on time trade-off valuations from a general population study conducted at the United Kingdom, which have been found applicable in the Greek setting [28] .
Analysis
Descriptive statistics (frequency, percentage, mean, standard deviation, median and interquartile range) were used for the analysis of the demographic and clinical characteristics of the sample, as well as the resource utilization and costs. To assess the effect of disability on costs and QoL of MS, along with demographic and clinical data, three categories were created based on EDSS score, as in previous studies [10] [11] [12] [13] 15] , i.e., those with mild (EDSS 0-3), moderate (EDSS 3.5-6) and severe disability (EDSS 6.5-7.5). We conducted Jonckheere trend tests to examine whether a significant trend existed (ordered pattern of alternatives) in continuous data with advancing severity of the disease, as it was measured with the EDSS groups described; Cochran-Armitage tests were used for categorical responses. Similarly, the differences between MS type groups were compared with Mann-Whitney and x 2 tests, for continuous and categorical data respectively. All comparisons were evaluated on the α=5% level. Confidence intervals (95%) of the costs were estimated by non-parametric bootstrapping. Statistical analysis was carried out with IBM SPSS Statistics 21 software package.
Results
Patient demographics and disease information
A total of 200 patients completed the study and were included in the analysis. Patients' socio-demographics and disease information are presented in (Table 2) . The sample had a mean age of 39.5 years, with 70.4% being females. The overall mean EDSS level was 3.1 (± 2.0), and the majority of subjects (62.5%) belonged to the mild disability subgroup (EDSS ≤ 3). Patients with less severe disease were younger (p<0.001); also the time period since first appearance of symptoms and diagnosis was shorter for less afflicted subjects (both p<0.001). A proportion of 86.5% was diagnosed as having RRMS, and 13.5% with SPMS. Finally, only 32% of the participants were employed or selfemployed at the time of the study.
The most frequently reported comorbidities were depression (50%), urinary problems (34.5%), sleep disturbance (27.5%) and cognitive impairment (21.5%). Urinary tract infections and osteoporosis increased with the EDSS disability level (p<0.05). On average, RRMS patients were experiencing comorbidities to a lesser extent, though the difference was found statistically significant only for osteoporosis (p<0.05).
Resource utilisation
About 30% of the patients had required a hospital admission due to MS during the previous year (Table 3) ; a proportion of 46% had received outpatient care in a hospital and 4.5% in a rehabilitation centre, while 64.5% had consulted a specialist. The majority of patients had received a Disease Modifying Treatment (DMT; 84%), and 29% non-prescription medicines in the previous 3 months and 1 month of the study, respectively; a proportion of 76% had at least one Magnetic 
Years since first diagnosis
Mean ± SD 9.2 ± 5. 
Years since first symptoms
Mean ± SD 11.9 ± 6.7 9.9 ± 6.1 15.1 ± 6.7 16.2 ± 5. 
Relapses requiring steroids in previous year
Mean ± SD 0.9 ± 0.9 0.8 ± 1.0 1.2 ± 1.0 0.5 ± 1.0 1.0 ± 1.0 0.6 ± 0.8 
MS related Comorbidities, n (%)
Median (IQR) 0 (3.0) 0 (3.0) 0 (4.0) 0 (0) 0.945 0 (3.0) 0 (0) 0.033
Hospital due to relapses
Mean ± SD 2.2 ± 3.4 2.0 ± 3.3 2.9 ± 3.5 1.3 ± 4.1 2.3 ± 3.4 1.5 ± 3.4 Rehabilitation centre, n % 9 (4.5%) 1 (0.8%) 5 (8.6%) 3 (17.6%) <0.001 7 (4.0%) 2 (7.4%) 0.433
Mean ± SD 1.2 ± 9.1 0 ± 0.4 3.7 ± 16.7 0.7 ± 1.6 1.3 ± 9.8 0.3 ± 1.1 Median visits (IQR)
Ergotherapist Mean visits ± SD 0.7 ± 10.2 0 ± 0 2.5 ± 18.9 0 ± 0 0.8 ± 10.9 0 ± 0
Neurologist Mean visits ± SD 3.7 ± 5.7 3.9 ± 6. Resonance Imaging Scan and 5.5% a Lumbar Puncture performed, in the previous 3 months. Advancing disability appears to increase significantly the utilisation of outpatient care (both hospital and rehabilitation centre) and co-medication, though statistical significance is not established in all cases. RRMS patients utilise medical resources to a greater extent compared with SPMS subjects (with the exception of most prescribed drugs), though again the level of statistical significance is not reached in most items.
Modification of living space or vehicle or use of walking aids due to MS was necessary for 14% of the subjects (Table 4) . The frequency of patients reporting any MS-related investment (p<0.001) and use of professional or informal care due to MS (both p<0.001) increased significantly with worsening severity of the disease; notably, utilization of informal care was much more frequently reported (39%) than professional care (6.5%). RRMS patients were receiving less informal and professional assistance (both p<0.001), and had less overall MSrelated modifications and equipment investments than the SPMS subjects (p<0.001). Apparently, due to higher disability level and lower relapse rate, SPMS patients require more informal care support rather than health care services utilisation.
About one third of the patients (31%) had been retired due to MS, and 33.5% reported receiving MS-related disability benefits during the time of the study (Table 5) ; both percentages were higher for patients experiencing SPMS (p<0.005). 14% of the subjects reported that they had taken a sick leave due to MS during the previous 3 months of the study; patients in a more severe condition recorded more sick days on average, though not statistically significant. A proportion of 9% of the sample reported a permanent reduction in work hours, and 5% listed a work change and/or income reduction due to the disease.
Costs
The mean cost per patient per year was estimated at €26,118, with Mean days ± SD 2.6 ± 11.7 1.9 ± 9.0 2.9 ± 12.6 6.5 ± 22.1 2.9 ± 12.5 0.5 ± 2.0 MS treatments being the largest contributor to the overall cost (48.4%) and for all disability and MS type subgroups (Tables 6 and 7) . Total cost increased significantly (p<<0.001) across the EDSS disability level groups; €20,702 for mild disability (EDSS 0-3), €32,126 for moderate disability (EDSS 3.5-6) and €45.442 for high disability patients (EDSS 6.5-7.5). Total direct medical and non-medical, and indirect costs all increased significantly with advancing disability (all p<0.05). The component costs of outpatient care, MS treatments, MS-related comorbidities, MA-related investments, professional and informal assistance and economic burden due to early retirement (disability pension) all enlarged significantly (all p<0.05) with increasing disability. Notably, the share of informal care in the total cost rose from 5.7% in patients with mild condition to 32.6% in subjects with severe disability (14.6% overall contribution).
Reduction in work hours, n (%)
RRMS subjects were on average less disabled than SPMS patients (EDSS mean score 2.7 vs. 5.9 respectively; Table 2), which is reflected in the lower costs observed in the RRMS subgroup; the mean cost per patient per year was €23,892 for RRMS and €40,381 for SPMS subjects respectively. Direct medical and non-medical as well as indirect costs all were significantly different between groups (all p<0.05); component costs of inpatient care and investigations were statistically significantly larger in RRMS patients (p<0.05), whereas economic burden due to MS-related investments, informal care and early retirement (disability pension) was greater in participants with SPMS (all p<0.05).
QoL
Anxiety/depression problems were reported by 74% of the patient population, while 67.5% had at least some mobility issues, 59% were experiencing usual activities limitations, 45% were complaining of pain/ discomfort and 27% had at least some self-care difficulties (Table 8) . The frequency of patients reporting problems with mobility, self-care and usual activities was increasing significantly with worsening disability (all p<0.001), and it was found higher in patients with SPMS (all p<0.001).
The mean utility score of the sample was 0.601 (± 0.287); HRQoL index decreased significantly with worsening disability (p<0.001), i.e., 0.683 (± 0.255) in mild, 0.508 (± 0.266) in moderate, and 0.316 (± 0.309) in high disability patients. SPMS group's HRQoL was more impaired than that of the RRMS (p<0.001); the mean EQ-5D index was 0.359 (± 0.318) and 0.639 (± 0.263) for SPMS and RRMS subjects respectively. VAS results concerning self-assessed health were in congruence with these findings; the mean VAS score of the whole sample was 67.9 (± 21.0), and a decreasing trend was again established with increasing severity (p<0.001). Finally, the SPMS group was associated with a significantly lower mean VAS score compared with the RRMS group (51.6 vs. 70.5, respectively; p<0.001).
Discussion
The objective of this study was to estimate the health and economic burden of MS in Greece, while offering valuable insights into the way disease severity and MS type affect the related costs.
The mean annual cost per patient was estimated at €26,118. This is comparable to the results of a recent study across 5 European countries, in which the mean annual cost per patient ranged between €20,738 and €29,400 [10] [11] [12] [13] [14] [15] . Worsening disability was associated with a substantially increased economic impact of the disease, which is in accordance with the findings of most published studies [10] [11] [12] [13] 15, 19, [29] [30] [31] [32] [33] [34] [35] [36] . According to the existing literature [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] , severe disability, when compared to mild, is associated with increased costs for hospitalizations, consultations, laboratory tests and other drugs, although the cost of immunomodulatory drugs is reduced. In our research, total direct medical and non-medical as well as indirect costs indeed increased considerably with advancing disability, with statistical significances established for the majority of their components. Furthermore, treatment cost retained its prominence in all disability and MS type subgroups, though its share in the total cost gradually decreased, which may be attributed to the patient recruitment, as it is discussed subsequently. Informal care contributed significantly to the total cost (14.6%); its contribution increased from 5.7% in patients with mild to 32.6% in subjects with severe disability, confirming the importance of informal care for MS patients, which is strongly associated with the severity of the disease [10] [11] [12] [13] [14] [15] 18, 19, [29] [30] [31] [32] [33] [34] [35] [36] . Higher mean disability in patients with SPMS compared with RRMS subjects resulted in almost doubled total costs, in congruence with what is observed in other European countries [10, [12] [13] [14] [15] ; total direct medical and non-medical as well as indirect costs all were significantly different between the 2 groups.
HRQoL was found considerably impaired by MS. Psychological and mobility problems and difficulties related to usual activities were reported by the majority of the patients. The mean utility score in the sample was 0.601 (VAS mean score 67.9), which is lower than the corresponding value in the general population, though somewhat higher than in other similar reports [16] [17] [18] [19] [20] 37 ], which could be attributed to the lower mean EDSS level of this study. Finally, higher severity and SPMS type of MS decreased HRQoL, which is consistent with the international literature [10] [11] [12] [13] [14] [15] 18, 19, [29] [30] [31] [32] [33] [34] [35] [36] .
There are several limitations related to the recruitment of patients from hospital MS centres, as it might result in a sample of subjects with higher mean disability [38] . Nevertheless, in our study, the number of patients which were assigned to the high disability group (EDSS 6.5-7.5) was relatively low (n=17). In fact, patients with EDSS >7.5 were not represented in our study, hence costs might has been actually underestimated due to the lack of high resource consuming patients. Currently, there are no country-scale studies of MS in Greece with epidemiological data concerning different patient disability categories, which could have been used as a demographic guide in the study design. Additionally, we approximated the productivity loss due to MS by the patient-reported reduction in their income, which may not be an appropriate proxy for estimating productivity losses, if there is a benefit to mitigate the fall in income.
Furthermore, the questionnaire explicitly requested resource utilization due to MS, but it still might have captured consumption unrelated to MS, thus yielding inflated costs. This possible limitation is particularly relevant to the comorbidities' economic burden, which was estimated as the total mean annual cost per patient, and not only as co-medication costs. Nevertheless, MS is a well-defined condition, and unrelated comorbidity is relatively low due to the young age of the patients [19, 38] . A degree of recall bias introduced by participants regarding their reports about past events or experiences may also be present, as it is a common peril among studies with a retrospective design [41] . Finally, the sample size of patients without a recent relapse was not large enough to estimate the specific cost related to relapses, which would have been a valuable piece of information.
